Effect of yeast-derived β-glucan in conjunction with bevacizumab for the treatment of human lung adenocarcinoma in subcutaneous and orthotopic xenograft models

Journal of Immunotherapy

Volumn 32, Issue 7, 2009, Pages 703-712

  Zhong, Wangjian ^a,b   Hansen, Richard ^a   Li, Bing ^a   Cai, Yihua ^a   Salvador, Carolina ^b   Moore, Grace D ^a   Yan, Jun ^a,b  

^a University of Louisville School of Medicine   (United States)

^b Division of Gynecologic Oncology   (United States)

Author keywords

Angiogenesis; Antitumor monoclonal antibody; B glucan

Indexed keywords

BETAFECTIN; BEVACIZUMAB; CETUXIMAB; COMPLEMENT COMPONENT C3 RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; VASCULOTROPIN;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COMPLEMENT DEPOSITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCID MOUSE; SURVIVAL TIME; TUMOR GROWTH; TUMOR XENOGRAFT; YEAST;

ADENOCARCINOMA; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BETA-GLUCANS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; COMPLEMENT ACTIVATION; HUMANS; LUNG NEOPLASMS; MICE; MICE, SCID; NEUTROPHIL INFILTRATION; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS; YEASTS;

EID: 68449085050     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181ad3fcf     Document Type: Article

References (40)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106-130.
2. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359:1367-1380.
3. American Cancer Society website, a. m., www.cancer.org/docroot/PRO/ content/PRO-1-1-Cancer-Statistics-2008-Presentation.asp, www.cancer.org/ downloads/PRO/LungCancer.pdf
4. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers - a different disease. Nat Rev Cancer. 2007;7:778-790.
5. NCI SEER database http://seer.cancer.gov/cgi-bin/csr/1975-2004/search. pl#results, a. m.
6. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92-98.
7. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70.
8. Folkman J. Tumor angiogenesis: therapeutic implications. N EnglJ Med. 1971;285:1182-1186.
9. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature. 2005;438:967-974.
10. Fontanini G, Vignati S, Boldrini L, et al. Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin Cancer Res. 1997;3:861-865.
11. Price DJ, Miralem T, Jiang S, et al. Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells. Cell Growth Differ. 2001;12:129-135.
12. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997;57:4593-4599.
13. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993;362:841-844.
14. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004;10:145-147.
15. Sandier A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542-2550.
16. Manegold C, von Pawel J, Zatloukal P, et al. Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapynaive patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704. J Clin Oncol (Meeting Abstracts). 2007;25:LBA7514.
17. Di Costanzo F, Mazzoni F, Micol Mela M, et al. Bevacizumab in non-small cell lung cancer. Drugs. 2008;68:737-746.
18. Yan J, Allendorf DJ, Brandley B. Yeast whole glucan particle (WGP) beta-glucan in conjunction with antitumour monoclonal antibodies to treat cancer. Expert Opin Biol Ther. 2005; 5:691-702.
19. Thornton BP, Vetvicka V, Pitman M, et al. Analysis of the sugar specificity and molecular location of the beta-glucanbinding lectin site of complement receptor type 3 (CDllb/CD18). J Immunol. 1996;156:1235-1246.
20. Xia Y, Vetvicka V, Yan J, et al. The beta-glucan-binding lectin site of mouse CR3 (CD11b/CD18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells. J Immunol. 1999;162:2281-2290.
21. Tsikitis VL, Morin NA, Harrington EO, et al. The lectin-like domain of complement receptor 3 protects endothelial barrier function from activated neutrophils. J Immunol. 2004; 173: 1284-1291.
22. Li B, Allendorf DJ, Hansen R, et al. Yeast beta-glucan amplifies phagocyte killing of iC3b-opsonized tumor cells via complement receptor 3-Syk-phosphatidylinositol 3-kinase pathway. J Immunol. 2006;177:1661-1669.
23. Yan J, Vetvicka V, Xia Y, et al. Beta-glucan, a "specific" biologic response modifier that uses antibodies to target tumors for cytotoxic recognition by leukocyte complement receptor type 3 (CD11b/CD18). J Immunol. 1999;163:3045-3052.
24. Hong F, Hansen RD, Yan J, et al. Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells. Cancer Res. 2003;63: 9023-9031.
25. Allendorf DJ, Yan J, Ross GD, et al. C5a-mediated leukotriene B4-amplified neutrophil chemotaxis is essential in tumor immunotherapy facilitated by anti-tumor monoclonal antibody and {beta}-glucan. J Immunol. 2005;174:7050-7056.
26. Li B, Allendorf DJ, Hansen R, et al. Combined yeast {beta}-glucan and antitumor monoclonal antibody therapy requires C5a-mediated neutrophil chemotaxis via regulation of decay-accelerating factor CD55. Cancer Res. 2007;67:7421-7430.
27. Cheung NK, Modak S. Oral (1 - > 3), (1 - > 4)-beta-D-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma. Clin Cancer Res. 2002;8:1217-1223.
28. Cheung NK, Modak S, Vickers A, et al. Orally administered beta-glucans enhance anti-tumor effects of monoclonal antibodies. Cancer Immunol Immunother. 2002;51:557-564.
29. Modak S, Koehne G, Vickers A, et al. Rituximab therapy of lymphoma is enhanced by orally administered (1 - > 3), (1 - > 4)-D-beta-glucan. Leuk Res. 2005;29:679-683.
30. Salvador C, Li B, Hansen R, et al. Yeast-derived {beta}-glucan augments the therapeutic efficacy mediated by anti-vascular endothelial growth factor monoclonal antibody in human carcinoma xenograft models. Clin Cancer Res. 2008;14:1239-1247.
31. Onn A, Isobe T, Itasaka S, et al. Development of an orthotopic model to study the biology and therapy of primary human lung cancer in nude mice. Clin Cancer Res. 2003;9:5532-5539.
32. Yano S, Shinohara H, Herbst RS, et al. Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells. Am J Pathol. 2000;157:1893-1903.
33. Matsumori Y, Yano S, Goto H, et al. ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model. Oncol Res. 2006;16:15-26.
34. Herbst RS, O'Neill VJ, Fehrenbacher L, et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol. 2007;25:4743-4750.
35. Sandier A. Bevacizumab in non small cell lung cancer. Clin Cancer Res. 2007;13:s4613-s4616.
36. Park JE, Keller GA, Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell. 1993;4: 1317-1326.
37. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669-676.
38. Neufeld G, Cohen T, Gengrinovitch S, et al. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999;13:9-22.
39. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25:1539-1544.
40. Zimmerman JW, Lindermuth J, Fish PA, et al. A novel carbohydrate- glycosphingolipid interaction between a beta-(1-3)-glucan immunomodulator, PGG-glucan, and lactosylceramide of human leukocytes. J Biol Chem. 1998;273:22014-22020.